|
OneSource Specialty Pharma in its consolidated financial results for Q4FY26 and full year ended March 31, 2026 has registered Rs. 428.2 crore up 47% QoQ and for the full year in FY26 reported a rise of 2 percent at Rs 1421.6 crore.
During the quarter, the growth was driven across all service offerings supported by India semaglutide commercial launch. For the full year FY26, the company reported a net loss of Rs. 73.8 crore.
Neeraj Sharma, CEO & MD, OneSource Specialty Pharma Limited speaking on the performance said, “We saw a strong recovery in Q4 driven by broad-based business performance. The quarter was marked by successful semaglutide launches in India across multiple customer brands, alongside new launches in the US injectables and soft-gelatin businesses. With the recent back-to-back semaglutide approvals in Canada and continued expansion of our biologics pipeline, we are well positioned to sustain growth momentum into FY27.”
|